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Abstract
Introduction Unclassified variants (UVs) in the BRCA1/BRCA2
genes are a frequent problem in counseling breast cancer and/
or ovarian cancer families. Information about cancer family
history is usually available, but has rarely been used to evaluate
UVs. The aim of the present study was to identify which is the
best combination of clinical parameters that can predict whether
a UV is deleterious, to be used for the classification of UVs.
Methods We developed logistic regression models with the
best combination of clinical features that distinguished a
positive control of BRCA pathogenic variants (115 families)
from a negative control population of BRCA variants initially
classified as UVs and later considered neutral (38 families).
Results The models included a combination of BRCAPRO
scores, Myriad scores, number of ovarian cancers in the family,
the age at diagnosis, and the number of persons with ovarian
tumors and/or breast tumors. The areas under the receiver
operating characteristic curves were respectively 0.935 and
0.836 for the BRCA1 and BRCA2 models. For each model, the
minimum receiver operating characteristic distance
(respectively 90% and 78% specificity for BRCA1 and BRCA2)
was chosen as the cutoff value to predict which UVs are
deleterious from a study population of 12 UVs, present in 59
Dutch families. The p.S1655F, p.R1699W, and p.R1699Q
variants in BRCA1 and the p.Y2660D, p.R2784Q, and
p.R3052W variants in BRCA2 are classified as deleterious
according to our models. The predictions of the p.L246V variant
in BRCA1 and of the p.Y42C, p.E462G, p.R2888C, and
p.R3052Q variants in BRCA2 are in agreement with published
information of them being neutral. The p.R2784W variant in
BRCA2 remains uncertain.
Conclusions The present study shows that these developed
models are useful to classify UVs in clinical genetic practice.
AUC: area under the curve; BC: breast cancer; bp1: BRCAPRO1 score; bp2: BRCAPRO2 score; BRCA: breast cancer gene; diag: age at diagnosis; 
myr: Myriad score; nbot: number of persons with ovarian and/or breast tumors; OC: ovarian cancer; ROC: receiver operating characteristic; tnot: total 
number of ovarian tumors; UV: unclassified variant.
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Introduction
Cancer risk counseling of patients and families with an unclas-
sified variant of the breast cancer (BC) genes BRCA1 and/or
BRCA2 (MIM numbers 113705 and 600185, respectively)
has become a prominent issue for genetic counselors and
oncologists. About one-third of the genetic variants in BRCA1
and 50% of those found in BRCA2 reported by the Breast
Cancer Information Core [1] are considered genetic variants
of unknown clinical significance, also known as unclassified
variants (UVs), because of the uncertainty about their cancer
risks. This is often the case for missense variations or when the
nucleotide change affects or creates a (putative) splice-site.
As opposed to the families with deleterious variants – where
asymptomatic relatives can be offered DNA diagnosis, and
carriers are eligible for risk-reducing interventions and/or sur-
veillance – presymptomatic testing is not possible in families
with a UV, and surveillance can only be based upon the sever-
ity of the cancer family history.
In addition to biochemical and epidemiological criteria [2-5],
information about co-segregation studies, co-occurrence with
a deleterious variant [6,7], loss of heterozygosity in the tumor
[8], histopathologic characteristics [9,10], and functional
assays [11,12] have been used to classify UVs. Several com-
prehensive models have been published that use combina-
tions of the above-mentioned parameters [6,7,9,12-14].
Limitations of those models can be that some of the parame-
ters included are not always available or are only suitable for
missense variants but not for other types of UVs.
Even though quantification of BC and/or ovarian cancer (OC)
events in the families is easy to record and is the most direct
sign of clinical relevance, cancer family history has only rarely
been used to classify UVs [14,15]. In a previous study [15] we
found that patients with a UV have, as a group, significantly
lower a priori scores using the BRCAPRO [16] and Myriad
[17] models than patients with a pathogenic variant. More
recently, Easton and colleagues have provided multifactorial
logistic regression models to classify UVs in the BRCA genes
[14]. Those models include information about the proband
(that is, disease status and age of diagnosis) and family his-
tory, which is categorized into n types, according to the
number of relatives with cancer (BC or OC) and the age of
diagnosis. The estimated likelihood ratio is combined with the
likelihood ratios obtained from the other two components of
the models – co-occurrence in trans with a known deleterious
mutation and co-segregation – to provide a global assessment
for each UV. This approach, which uses those parameters
most directly associated with the clinical outcome, has
recently been extended to UVs in other cancer genes [18].
In the present study, we have elaborated logistic regression
models using the most discriminative clinical features that dis-
tinguish between deleterious and neutral variants in BRCA1
and BRCA2. Subsequently, we have applied them to a group
of 12 UVs found in 59 Dutch families with BC and/or OC.
Materials and methods
Subjects
All of the probands from the families included in the study had
been selected for DNA diagnosis of BRCA1 and BRCA2,
according to the same selection criteria defined by a group of
experts and used nationwide. These criteria are based on the
number of first-degree and/or second-degree relatives with
BC and/or OC, and the age of diagnosis. Each of the indica-
tion criteria corresponds with at least a 10% chance of finding
a mutation in those genes.
Control populations
Families diagnosed and counseled at the Academic Medical
Center of Maastricht were used as controls. Table 1 presents
the clinical parameters evaluated in the control populations.
The positive control group consisted of 115 unrelated
probands with a deleterious variant (65 with a variant in
BRCA1 and 50 with a variant in BRCA2) and included 62 dif-
ferent mutations (29 mutations in BRCA1 and 33 mutations in
BRCA2). The negative control group consisted of 38 index
cases (20 cases in BRCA1 and 18 cases in BRCA2) with 19
different genetic variants (eight with a variant in BRCA1 and
11 with a variant in BRCA2) that were initially classified as
UVs, but later were considered neutral variants. For a detailed
description of the sequence variants included, we refer to Fig-
ures 1 and 2.
The total numbers of first-degree and second-degree relatives
in each of the control populations were 2,619 in the deleteri-
ous (positive control) population and 798 in the neutral variant
(negative control) populations.
Study population: patients with an unclassified variant
Each diagnostic laboratory in the Netherlands selected five
UVs in either BRCA1 or BRCA2 that were of particular inter-
est for that center (for example, multiple families with the same
UV, large families in which the UV was segregating). A list was
made that contained all of the selected UVs. From this list was
made a shortlist with those UVs that were present in several
centers and/or met at least one of the following criteria:
Grantham score >100 [19]; the UV is located within a struc-
tural domain (for example, BRCA C-terminal region domains in
BRCA1 or the BRC repeats in BRCA2) or in a domain that is
necessary for interaction with other proteins (for example,
RAD51 binding sites in BRCA1 and BRCA2) [20]; and the
amino acid change has a high degree of evolutionary conser-
vation (that is, invariant through Tetraodon nigroviridis) [21].
UVs co-occurring with a BRCA deleterious variant in the
proband were excluded. In addition, priority was given to those
UVs found in more than one family and/or genetic center.
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The UVs selected (four in BRCA1 and eight in BRCA2) were:
BRCA1: ex.11:c.736T>G (p.L246V), ex.16:c.4964C>T
(p.S1655F), ex.18:c.5095C>T (p.R1699W), and
ex.18:c.5096G>A (p.R1699Q); and BRCA2: ex.3:c.125A>G
(p.Y42C), ex.10:c.1385A>G (p.E462G), ex.18:c.7978T>G
(p.Y2660D), ex.19:c.8350G>A (p.R2784W),
ex.19:c.8351C>T (p.R2784Q), ex.21:c.8662C>T
(p.R2888C), ex.24:c.9154C>T (p.R3052W), and
ex.24:c.9155G>A (p.R3052Q). The nomenclature used for
the description of the sequence variations is that according to
the Human Genome Variation Society [22].
Table 2 summarizes the available biochemical and epidemio-
logical data of the UVs. Please note that the p.L246V
(BRCA1) and the p.E462G (BRCA2) variants did not meet
any of the criteria mentioned above, but were selected
because those UVs were found in more than one genetic
center. During the course of our study, the p.R1699W in
BRCA1 was reclassified as pathogenic in the Breast Cancer
Information Core [1].
All patients included in this study gave informed consent and
the study was approved by the Medical Ethical Committees of
the medical centers.
The same clinical parameters analyzed in the control popula-
tion were also collected in the families of the study population.
The total number of first-degree and second-degree relatives
was 1,082.
Laboratory diagnosis
BRCA1 and BRCA2 were analyzed from blood samples by
denaturing high-performance liquid chromatography. Addi-
tional technical details, primers and denaturing high-perform-
Table 1
Descriptive statistics
Pathogenic variants (positive controls) Neutral variants (negative controls) P value
Number of probands Mean ± standard deviation/
percentage
Number of probands Mean ± standard deviation/
percentage
Proband data
BRCAPRO score alla 115 0.580 ± 0.353 38 0.381 ± 0.219 0.000
BRCAPRO1 scorea 65 0.472 ± 0.300 20 0.293 ± 0.155 0.000
BRCAPRO2 scorea 50 0.244 ± 0.186 18 0.163 ± 0.123 0.001
Myriad II scorea 115 0.241 ± 0.145 38 0.174 ± 0.094 0.000
Sex (male)b 115 3.5 38 0 0.000
BCb 115 80.9 38 84.2 0.810
Bilateral BCb 115 14.8 38 18.4 0.611
Age at BC diagnosisc 93 43.419 ± 10.208 32 46.178 ± 9.591 0.008
OCb 115 18.3 38 5.3 0.066
Age at OC diagnosisc 21 54.381 ± 9.967 2 48.190 ± 9.899 0.108
Family data
Members affectedd 115 3.548 ± 1.640 38 3.234 ± 1.124 0.056
Proportion affecteda 115 0.183 ± 0.094 38 0.173 ± 0.078 0.199
Number of tumorsd 115 4.200 ± 1.957 38 3.732 ± 1.329 0.007
Total BC tumorsd 115 3.400 ± 2.021 38 3.266 ± 1.277 0.422
Bilateral BCd 115 0.435 ± 0.637 38 0.375 ± 0.620 0.279
BC in malesb 115 10.4 38 2.6 0.820
Age at BC diagnosisc 115 45.607 ± 7.951 38 48.623 ± 7.577 0.000
Total OC tumorsd 115 0.800 ± 0.929 38 0.466 ± 0.343 0.000
Age at OC diagnosisc 64 52.982 ± 10.323 5 51.091 ± 11.234 0.435
BC, breast cancer; OC, ovarian cancer. aUnivariate gamma linear regression model (t test). bTwo-by-two table (Fisher's exact test). cUnivariate 
Gaussian linear regression model (t test). dUnivariate Poisson linear regression model (z test).
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ance liquid chromatography elution profiles are available from
the authors upon request. Changes in denaturing high-per-
formance liquid chromatography elution profiles were verified
by standard sequence analysis. Until 10 years ago, a protein
truncation test was used to analyze exon 11 of BRCA1 and
exons 10 and 11 of BRCA2. In those cases, the rest of the
gene was more recently fully analyzed by denaturing high-per-
formance liquid chromatography. In addition, multiplex ligation-
dependent probe amplification analysis was performed for
BRCA1 to detect large duplications or deletions.
Statistical analysis
The BRCAPRO and Myriad models are distributed as a part of
the counseling package CancerGene from the U.T. South-
western Medical Center at Dallas [16,17].
BRCAPRO [16] is a Mendelian model that incorporates
mutated allele frequencies and cancer-specific penetrances,
in addition to the following clinical parameters about the
proband and the first-degree and second-degree relatives: the
number of women affected with BC only; the number of
women affected with OC only; discrimination between pater-
nal/maternal inheritance patterns; BC under age 50 and OC
(any age); bilateral BC; a relative with both OC and BC;
affected and unaffected individuals; Ashkenazi Jewish ances-
try; and male BC.
The Myriad II prevalence tables [17] are based on proband
and family history accompanying results of BRCA1 and
BRCA2 deleterious variant samples tested by the company.
Unlike the BRCAPRO model, these tables do not include bilat-
eral BC and BCs diagnosed when the patient is older than 50
Figure 1
Predicted probabilities of the BRCA1 control populations. Plot showing the predicted probabilities of the control populations – deleterious (muta-
tions) and neutral variants (polymorphisms) – in BRCA1 using the logistic regression model obtained for BRCA1. Dotted cutoff lines, probability 
from the BRCA1 model that minimizes the receiver operating characteristic (ROC) distance. For each genetic variant, the number of families above 
the cutoff point and the total number of families (n/N) is presented on the right side along with the probability of having at least one correct predic-
tion (Prob.) and the probability if all families of the genetic variant under consideration were on the cutoff point (threshold). Finally, the classification 
(C) as a deleterious variant (D) or not known (N) is also presented. Sequence nomenclature: NCBI reference sequence U14680.1 (BRCA1), num-
bering starting at the A of the ATG translation initiation codon.
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years old in the calculation, and inclusion is restricted to a max-
imum of three relatives, including the patient. In addition, the
tables do not calculate BRCA1 and BRCA2 probabilities sep-
arately.
The descriptive analysis for the two control populations was
made using a Gaussian, Poisson, and Gamma linear model
for: continuous, count, and percentage variables, respectively.
The differences between the group with a pathogenic variant
and the group with a neutral variant were obtained using a t
test, a z test, and a t test for the Gaussian, Poisson, and
Gamma models, respectively. Finally, binary variables were set
up as two-by-two tables and the difference between groups
was assessed using Fisher's exact test.
A logistic regression was fitted to the pathogenic variations
and neutral variants in order to elaborate a predictive model for
the pathogenicity of the UVs. The inference criterion used for
comparing the models is their ability to predict the observed
data; that is, models are compared directly through their mini-
mized minus log-likelihood. When the numbers of parameters
in models differed, they were penalized by adding the number
of estimated parameters – a form of the Akaike information cri-
terion [23].
Three predictive models (one for variants in both BRCA1 and
BRCA2 and one for each of these separately) were con-
structed using the best combination of variables that distin-
guished between deleterious and neutral variants. This was
done by first fitting separate univariate models for each clinical
feature as well as for BRCAPRO and Myriad scores. To estab-
lish which parameters are the most significant ones to predict
the pathogenicity of a specific UV, the explanatory variables
found to be significant in the univariate analysis are ranked
according to their Akaike Information Criterion and are entered
Figure 2
Predicted probabilities of the BRCA2 control populations. Plot showing the predicted probabilities of the control populations in BRCA2 using the 
logistic regression model obtained for BRCA2. Dotted cutoff lines, probability from the BRCA2 model that minimizes the receiver operating charac-
teristic (ROC) distance. The parameters evaluated for the BRCA1 variants (explained in Figure 1) are also shown for each of the BRCA2 genetic 
variants. Sequence nomenclature: NCBI reference sequence U43746.1 (BRCA2), numbering starting at the A of the ATG translation initiation 
codon.
Br
e
a
s
t
 
C
a
n
c
e
r
 
R
e
s
e
a
r
c
h
 
 
 
 
V
o
l
 
1
1
 
N
o
 
1
 
 
 
 
G
ó
m
e
z
 
G
a
r
c
í
a
 
e
t
 
a
l
.
P
a
g
e
 
6
 
o
f
 
1
2
(
p
a
g
e
 
n
u
m
b
e
r
 
n
o
t
 
f
o
r
 
c
i
t
a
t
i
o
n
 
p
u
r
p
o
s
e
s
)
Table 2
The unclassified variants in the present study: epidemiological and biochemical criteria
Variant [22] Number 
of families
Co-segregation 
(present study)a
Polarity 
change
Conserved 
mammals/other 
[21]b
Grantham 
score [19]
Times reported 
(Breast Cancer Information Core [1])
Co-segregation 
(literature)
Co-occurrence 
(literature)
Classification 
(literature)
Referencec
BRCA1
p.L246V 2 ND No No/No 32 79 No Yes (several) Neutral [5,7,13]
p.S1655F 2 6/6 (n = 2) Yes Yes/Yes 155 3 Not done Not done Deleterious [5,32,34,35]
p.R1699W 9 8/8 (n = 4) Yes Yes/Yes 101 13 Not done No Deleterious [1,14,35]
p.R1699Q 5 1/2 (n = 2)d Yes Yes/Yes 43 11 Yes No Deleterious, 
uncertain, low/
moderate
[5,6,9,12,32,34,35]
Total 18
BRCA2
p.Y42C 3 ND N No/No 194 14 No Yes Neutral [6,9,11]
p.E462G 8 2/5 (n = 5) Yes Yes/No 98 35 No Yes (Y3097X) Neutral [11,12]
p.Y2660D 9 8/8 (n = 5) Yes Yes/Yes 160 2 Not done Not done None
p.R2784W 1 ND Yes Yes/Yes 101 5 Not done Not done Uncertain [33]
p.R2784Q 4 1/2 (n = 2)e Yes Yes/Yes 43 4 Not done Not done None
p.R2888C 5 1/1 (n = 1) Yes No/Yes 180 4 No Yes Neutral [14]
p.R3052W 10 1/1 (n = 1) Yes Yes/Yes 101 8 Not done Not done Deleterious [33]
p.R3052Q 1 0/1 (n = 1) Yes Yes/Yes 43 3 Not done Yes Neutral [14]
Total 41
aCo-segregation in the present study is expressed as number of tested positive (proband excluded)/total number of affected relatives tested (n = number of families tested). bAlignments based on the 
following species and NCBI reference sequences: BRCA1: human (NP_009225), chimp (AAG43492), gorilla (AAT44835), orang (AAT44834), macacque (AAT44833), dog (AAC48663), mouse 
(AAD00168), cow (NP848668), opossum (AAX92675), chicken (NP989500), xenopus (AAL13037), and pufferfish (AAR89523); and BRCA2: human (NP000050), chimp (XP509619), dog (BAB91245), 
mouse (AAB48306), chicken (AAL89470), and tetraodon (CAG09009). cFunctional studies were performed in [11,12,32-35]. dLack of co-segregation was observed in one of the two pedigrees analyzed. 
In that pedigree, the proband had BC at age 37, her father's sister had BC at age 61, her cousin (the daughter of that aunt) had BC at age 45 – did not have the UV. eThis UV does not co-segregate with the 
disease in one family, which consisted of two affected members: the proband had BC at age 31, her mother with BC at age 67 – did not have the UV.
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accordingly into a new model. This was carried out following a
stepwise regression approach.
The receiver operating characteristic (ROC) curves were plot-
ted (data not shown) and the area under the curve (AUC) was
calculated for each of the three final models constructed for
the control and validation populations.
From a clinical point of view, the most important therapeutic
consequences are associated with the assessment of a UV
being deleterious. A cutoff point therefore needs to be defined
in order to detect the families having a deleterious variant with
a high degree of certainty rather than being very sensitive and
therefore less specific. The minimum ROC distance ((Sp-1)2 +
(1-Se)2) is calculated from the control populations for each
final model obtained from the stepwise regression as the cut-
off point. Families with a probability value situated above the
cutoff point are then predicted to have a deleterious variant
with high degree of certainty. This does not, however, neces-
sarily mean that the deleterious variant predicted is the UV
identified in that family. Conversely, no prediction can be made
as to whether a family has a deleterious or a neutral variant if
the value obtained lies under the cutoff point.
When a UV is present in several families, a prediction can be
made about whether that UV found is deleterious with more
certainty than if it is present in a single family. In order to per-
form a classification at the UV level, two additional probabili-
ties were computed from the model predictions. The first was
the probability that at least one prediction was correct:
 where Pi is the obtained predicted probability
for family i of the UV under consideration. The second proba-
bility to be computed (which will be referred to as the thresh-
old) is similar but replaces the predicted probabilities by the
corresponding cutoff value: 1-(1-CO)n where CO is the cutoff
probability and n is the total number of families with the variant
under consideration. The variant under consideration is then
classified as deleterious if the first probability computed is
above the threshold.
In the case of a variant with a single family, the model comes
back to comparing the predicted probability with the cutoff
point. A conclusion should therefore be made with great care
in such cases.
All statistical analyses presented were performed using the
freely available program R [24] and the publicly available
library 'gnlm' [25].
Results
Model building
To build a predictive model, a series of 115 unrelated
probands with a pathogenic variant (that is, a mutation) in
BRCA1 (n = 65) or in BRCA2 (n = 50) are compared with
those of a series of 38 unrelated probands with a neutral vari-
ant (that is, polymorphism) in BRCA1 (n = 20) or in BRCA2
(n = 18). Three models are constructed. A model is first fitted
for both BRCA1 and BRCA2 together, and then for each of
these separately (see Table 3).
Model for BRCA1
The model contains the BRCAPRO1 score (bp1), the total
number of ovarian tumors (tnot), the age at diagnosis (diag),
and the interaction between BRCAPRO1 and the age at diag-
nosis:
where .
The highest specificity to predict whether a UV is deleterious
that could be obtained with the BRCA1 model was 90%,
which corresponds to a probability of 0.469 (see Figure 1).
The AUC of the ROC curve for the BRCA1 model was 0.935,
and the lower and upper 95% confidence interval boundaries
were respectively 0.91 and 0.96.
Model for BRCA2
The model contains the BRCAPRO2 score (bp2), the Myriad
score (myr), and the number of persons with both ovarian
tumors and/or breast tumors (nbot):
where .
The highest specificity to predict whether a UV is deleterious
that could be obtained with the BRCA2 model was 89%,
which corresponds to a probability of 0.45 (see Figure 2). The
AUC of the ROC curve for the BRCA2 model was 0.836, and
the lower and upper 95% confidence interval boundaries were
respectively 0.784 and 0.887.
Model validation
Model validation was performed with the UVs from the present
study that had been classified in the literature. From the 12
UVs included in the study, published information about the UV
being either deleterious or neutral has become available in the
meantime for eight of them: p.L246V, p.S1655F, and
p.R1699W in BRCA1, and p.Y42C, p.E462G, p.R2888C,
p.R3052W and p.R3052Q in BRCA2 (see Table 2). We used
this information to validate our logistic regression models. The
1 1− −∏( )Pi
i
1
1 12 34 2 49 1 3 09 0 24  exp   logit bp   tnot    d+ − − − × − × + ×( ( . . ( ) . . iag    logit bp   diag+ × ×0 04 1. ( ) ))
logit x log x
x
( )= ( )
−1
1
1 3 33 0 57 0 57  exp   logit bp2   logit m yr  -10.9+ − − − × − ×( ( . . ( ) . ( ) 9  nbot× ))
logit x log x
x
( )= ( )
−1
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classification as deleterious or not known was therefore com-
puted from the appropriate model for each of these UVs, as
shown in Figures 3 and 4.
Amongst the UVs in BRCA1, the two families with the
p.L246V variant have predicted probabilities below the cutoff
point. The families with the p.S1655F and p.R1699W variants
are all predicted above the cutoff point (Figure 3). When com-
puting their probabilities (explained above in Materials and
methods), the p.S1655F and p.R1699W variants are classi-
fied as being deleterious (that is, their probabilities lie above
the thresholds) – as opposed to the p.L246V variant, which
cannot be classified (that is, probability below the threshold)
(see Figure 3). This classification matches previously pub-
lished results (Table 2). The AUC of the ROC curve for the
BRCA1 model is 1.000.
Amongst the UVs in BRCA2, all families belonging to the
p.Y42C and p.R3052Q variants have predicted probabilities
below the cutoff point. For both the p.E462G and p.R2888C
variants, only one family is predicted above the cutoff point;
and for the p.R3052W variant, four out of the nine families are
predicted above the cutoff point (Figure 4). When comparing
their probabilities, the p.R3052W variant is classified as being
deleterious – whereas the p.Y42C, p.E462G, p.R2888C, and
p.R3052Q variants cannot be classified. This also matches
previously published results (see Table 2). The AUC of the
Table 3
Model building steps
Number of parameters Akaike information criterion
Both BRCA1 and BRCA2 BRCA1 BRCA2
Intercept 1 86.76 47.38 40.30
Sex 2 86.60 48.11 40.35
Proband breast cancer or ovarian cancer 2 87.75 48.37 41.22
Proband breast cancer 2 87.65 48.16 41.30
Proband bilateral breast cancer 2 87.62 48.32 41.06
Proband ovarian cancer 2 85.49 46.84 40.57
Family affected 2 86.19 45.05 41.29
Number of first-degree and second-degree relativesa 2 87.45 47.93 41.26
Total number of family members affecteda 2 85.13 47.99 38.40
Proportion of family members affecteda 2 86.99 48.30 40.32
Total number of tumors (including bilateral) 2 83.58 47.93 36.24
Total number of breast tumors 2 87.46 47.82 38.90
Number of persons with bilateral cancer 2 87.23 48.17 38.61
Total number of ovarian tumors (tnot) 2 74.76 38.08 38.04
Number of persons with ovarian and/or breast tumors (nbot) 2 83.17 46.35 38.29
BRCAPRO score 2 67.36 35.90 33.74
Myriad score 2 69.17 36.84 34.25
Age at diagnosis (diag) 2 82.38 42.44 40.72
BRCAPRO + Myriad 3 66.30 35.55 33.30
BRCAPRO + Myriad + tnot 4 64.58 34.32 -
BRCAPRO + Myriad + tnot + diag 5 62.46 29.10 -
BRCAPRO + Myriad + tnot + diag + BRCAPRO:diag 6 - 28.29 -
BRCAPRO + tnot + diag + BRCAPRO:diag 5 - 27.51 -
BRCAPRO + Myriad + nbot 4 - - 33.16
Bold numbers represent the univariate and multiple regression models with the lowest Akaike information criterion. Italic numbers represent 
univariate regressions models with Akaike information criterion lower than that of the corresponding model. aAffected families only.
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Figure 3
Predicted probabilities and classification of the BRCA1 unclassified variants from this study
variants from this study. Box-plots for the BRCA1 unclassified variants 
(UVs) along with the control groups of deleterious and neutral variants. 
Dotted cutoff lines, probability from the corresponding model that mini-
mizes the receiver operating characteristic distance. The median of 
each UV and of the control groups (mutations and neutral variants) are 
presented below. In addition, the number of families above the cutoff 
point and the total number of families (n/N) is presented along with the 
probability of having at least one correct prediction (Prob.) and the 
probability if all families of the UV under consideration were on the cut-
off point (threshold). Finally, the classification (C) as a deleterious vari-
ant (D) or not known (N) is also presented. The UVs that have been 
reported to be either deleterious or neutral in the literature are dis-
played in bold.
Figure 4
Predicted probabilities and classification of the BRCA2 unclassified variants from this study
variants from this study. Box-plots, probability values and classification 
of the BRCA2 unclassified variants (UVs), as explained in Figure 3.
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ROC curve for the BRCA2 model is 0.789 (95% confidence
interval = 0.693 to 0.884).
Classification of unknown variants from the present 
study
Three out of the five families with the p.R1699Q variant in
BRCA1 had predicted probabilities above the cutoff point.
This UV was classified as deleterious (Figure 3).
The families with the p.Y2660D in BRCA2 had the highest
median of all the BRCA2 UVs from this study (median =
0.916), with eight of the nine families predicted above the cut-
off point. The computed probabilities classified this UV as
being deleterious (Figure 4).
The p.R2784W variant in BRCA2 could not be classified
because the only family with this variant was predicted below
the cutoff point (Figure 4).
Finally, two out of the four families with the p.R2784Q variant
in BRCA2 had predicted probabilities above the cutoff point.
This UV was classified as deleterious (Figure 4).
Discussion
About the models
Registration of BC and/or OC events in a family is easy to per-
form and is the most direct tool to assess the clinical signifi-
cance of a genetic variation. In the present study we
developed logistic regression models with the best combina-
tion of clinical features that distinguish families with deleteri-
ous variants from those with neutral variants, and applied them
to assess the pathogenicity of 12 UVs found in 59 Dutch fam-
ilies.
To estimate which families with a UV have features similar to
those with a proven deleterious mutation, we chose probands
with neutral variants as negative controls. In the study of Eas-
ton and colleagues, the negative controls were probands with
a wild-type genotype [14]. Although the size of the negative
control population would have been larger with the latter pop-
ulation, we consider a population with rare neutral variants to
be a better negative control to classify UVs, which are also rare
variants.
The BRCAPRO and Myriad II scores are useful tools for calcu-
lating the probability of finding a pathogenic variant [26-31], as
well as for distinguishing deleterious variants from UVs as a
group [15]. In the present study we show that these scores are
also useful for the classification of individual UVs. Our model
for BRCA1 performs better than the one for BRCA2 to predict
the deleterious effect of UVs, which is in line with the reduced
penetrance of the BRCA2 pathogenic variants. Accordingly,
Kang and colleagues [30] and James and colleagues [31]
have also reported that the BRCAPRO and Myriad models
perform better for predicting BRCA1 than BRCA2 patho-
genic variants.
By testing UVs that are present in multiple families, as is the
case for most of the UVs in the present study, the effect of pos-
sible confounders linked to a particular family can be over-
come. Confounders can result in either high or low false
probabilities. A false low probability can occur when the BRC-
APRO and Myriad II models are not able to incorporate impor-
tant information about the cancer history in a particular family
(for instance, if there is no information about relatives or if the
affected relatives are only third-degree relatives). Conversely,
when the BRCAPRO and Myriad models adequately reflect
the cancer history of the families with low scores, one has to
think of a possible confounder whenever the high score in one
of the families is discordant with the rest for a particular UV. In
those cases, information about co-segregation with the dis-
ease can give the answer as to whether the UV found is the
actual cause of the disease in that/those particular family(ies)
or the high scores are the result of another, as yet unidentified,
deleterious mutation. Indeed, the sensitivity of genetic testing
has been estimated to be at least 85%, with false negatives
including mutations of as yet unidentified cancer genes [26].
To account for the possibility that a mutation has escaped
detection, therefore, we recommend that more than a single
family with the same variant has to be available in order to be
able to classify the variant under consideration.
About the unclassified variants
Unclassified variants from the validation set
From the UVs included in the validation set, the p.S1655F and
p.R1699W variants in BRCA1 and the p.R3052W variant in
BRCA2 were classified as deleterious with our model. Abkev-
ich and colleagues [5] and Glover [32] have also reported on
the p.S1655F variant and considered it deleterious. The
p.R1699W BRCA1 variant has already been classified as del-
eterious in the Breast Cancer Information Core [1]. The
p.R3052W variant of BRCA2 has also been recently classi-
fied as deleterious based on a functional assay that measures
the DNA-repair function by homologous recombination [33].
Conversely, the remaining five UVs – p.L246V in BRCA1, and
the p.Y42C p.E462G, p.R3052Q, and p.R2888C variants in
BRCA2 – could not be classified. The fact that all five variants
have been reported to be neutral variants in the literature [5-
7,9,11-14] validates the sensitivity and specificity of our mod-
els.
Classification of the unknown variants
The p.R1699Q BRCA1 variant was classified as deleterious
according to our model. Earlier attempts to classify this partic-
ular UV have not lead to a uniform conclusion
[5,6,9,12,32,34,35]. Abkevich and colleagues [5] consider it
to be deleterious, whereas for Goldgar and colleagues [6],
Chenevix-Trench and colleagues [9], Glover [32], and Clap-
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perton and colleagues [34] the R1699Q genetic variation
remains of uncertain significance. Vallon-Christersson and col-
leagues [35] find a discrepancy in the transactivation activity
depending on the type of cells transfected with this UV: yeast
cells (neutral) or mammalian cells (deleterious). For Lovelock
and colleagues, this variant has low to moderate risk of being
pathogenic based on functional analysis; that is, p.R1699Q
appeared defective in nuclear foci formation using trypsin sen-
sitivity analysis as a result of BRCA C-terminal region destabi-
lization [12]. By referring to it as low to moderate risk, the
authors imply that genetic variations can have different
degrees of pathogenicity (that is, penetrance) [12]. We agree
with this hypothesis – that certain missense genetic variations
may have a milder effect than stop-codon variations, and there-
fore show intermediate features. This hypothesis may explain
the discordant conclusions among the different studies about
this UV (and possibly others as well) of being either deleteri-
ous or neutral. In the case of this particular UV, a factor of
uncertainty is also the lack of co-segregation in one family.
The p.Y2660D variant in BRCA2 is considered deleterious
according to our model. This UV has not been studied before.
In addition, this UV showed full co-segregation in the five fam-
ilies studied and it affects a highly conserved amino acid,
which also corroborate that this UV is deleterious.
The p.R2784Q variant in BRCA2 is also considered deleteri-
ous according to our model. This UV has not been classified
before. From a biochemical point of view, arguments in favor
of causality are that the arginine at that position is highly con-
served and that the amino acid substitution causes a polarity
change.
Neither the predicted probabilities nor the limited number of
families allowed definitive conclusions to be made about the
p.R2784W variant. Functional studies performed for this vari-
ant were also inconclusive [33].
Conclusions
We have identified a combination of variables from the cancer
history of the probands and their families that significantly dis-
tinguish families with proven deleterious variants from those
with neutral variants, and we have used them to develop logis-
tic regression models to classify individual UVs in the BRCA
genes. We used these models to classify a selected group of
12 UVs, the majority present in multiple families in the Nether-
lands. Using those models the p.S1655F and p.R1699W var-
iants in BRCA1 were classified as deleterious, which
corroborates previous literature reports. According to our
model, the p.R1699Q variant is also classified as deleterious
– but previous reports about this UV have been contradictory.
The p.Y2660D and p.R2784Q variants in BRCA2, which have
not been reported before, were also classified as deleterious.
From the six UVs that could not be classified, five (the p.L246V
variant in BRCA1, and the p.Y42C, p.E462G, p.R2888C, and
p.R3052Q variants in BRCA2) have been reported in the liter-
ature as being neutral variants. The p.R2784W variant in
BRCA2 remains uncertain.
Since the parameters evaluated are readily available, we con-
sider those developed models a useful tool to evaluate mis-
sense variants in the clinical genetic practice. Moreover,
because those parameters can be evaluated in families with all
types of UVs, those models are potentially suitable for the clas-
sification of all types of UVs.
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